News & Events

Product News

Product News

Highlights of 2015 in iCell® Cardiomyocytes Publications

A review of the literature for the most interesting published applications utilizing iCell Cardiomyocytes in 2015


Label-free Assessment of Cardiomyocyte Activity

Understanding and defining the effects of compounds on cardiac function is critically important in drug discovery and toxicity testing. CDI’s iCell Cardiomyocytes and iCell Cardiomyocytes2 provide a relevant and validated system for studying pharmacological effects on human cardiomyocyte activity.

iCell® Hepatocytes 2.0: Now in 3D!

The world of iPSC-derived hepatocytes is no longer flat. CDI has identified protocols enabling the formation of stable 3D spheroids in culture.

iCell® Skeletal Myoblasts: A Model for Interrogating and Modulating Glucose Uptake

CDI’s iCell® Skeletal Myoblasts provide an excellent model for investigating the etiology, pathology, and potential treatments of type 2 diabetes while Promega’s Ultra-Glo™ reagents offer easy-to-use, highly sensitive, and robust detection reagents for a variety of cellular processes.

1536-well Screening Assays with iCell Cardiomyocytes2

High Throughput Screening Applications: Learn how to use iCell Cardiomyocytes2 in 1536-well screening assays.

Non-invasive Video Analysis of Beating Cardiomyocytes

Learn about recently released methodology for video analysis of cardiomyocyte function.

Pacing iCell Cardiomyocytes

Foreseeing drug-induced arrhythmia is a critical component of drug development and the FDA is seeking to increase the predictivity of pre-clinical testing strategies via the Comprehensive In Vitro Proarrhythmia Assay (CIPA) initiative.

Induced Hypoxia and Screening for Cardioprotection

Myocardial ischemia is a pathological condition characterized by a reduced oxygen supply that can lead to cellular apoptosis/necrosis, arrhythmia, organ injury, and even death.

Comprehensive In Vitro Proarrhythmia Assay (CIPA)

The primary goal of the CIPA initiative is to utilize mechanistic understanding of cardiac electrophysiology to create a more predictive biomarker for drug-induced Torsades de Pointes (TdP). The current biomarkers of hERG ion channel block and QT prolongation are highly sensitive endpoints with low selectivity and thus potentially result in unnecessary attrition.